Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer

Namrata S. Patil(Gene Therapy Laboratory), David S. Shames(Gene Therapy Laboratory), Allison W. Hsia, Shyam Srivats, Sören Müller(Genesys (United States)), Chikara Takahashi, Sangeeta Jayakar, Maureen Peterson, Hartmut Koeppen, Romain Banchereau(Kaiser Permanente San Francisco Medical Center), Jennifer M. Giltnane(Beth Israel Deaconess Medical Center), Avantika S. Chitre, Amelia Au‐Yeung, William O’Gorman(Genomic Health (United States)), Jason Cheng, Wei Zou, Linda Rangell, Jane L. Grogan(Biogen (United States)), Patrícia E. de Almeida, Marcus Ballinger, Barzin Y. Nabet(Gene Therapy Laboratory)

Cancer Cell

February 24, 2022

10.1016/j.ccell.2022.02.002

Cited by 403

Related Papers

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

|The Lancet|2016|4.8k

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

|New England Journal of Medicine|2018|3.5k

The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells

|Nature Immunology|2008|1.5k

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

|The Lancet|2017|1.4k

Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab

|Nature Medicine|2018|1.2k